Number ofblastspresent inacceleratedphaseThis TKI hasthe mostmetabolicsyndromeTherecommendedcriteria usedfor acceleratedphaseAfter 3months, I have3% BCR-ABL,I have this TKIresponseModerateto highemetogenicrisk TKIsPercentageof blastspresent inthe blastphaseDrug classthatrevolutionizedCMLtreatmentI avoid thisdrug classwith bosutinib,nilotinib anddasatinibI want toavoid thisTKI if I donot wantdiarrheaThelandmarkfor thefirst TKINon-pharmacologicaltreatment forCMLToo many ofthese bloodcells areabnormal inCMLResponsewhen BCR-ABL1 (IS)is <0.01%Patients havepresence of thisBCR-ABLproteinindicative ofCML TKIs aremajorsubstratesfor this liverenzymeThe numberof distinctclinicalphases inCMLTreatmentfor blastphaseCMLTranslocationbetweenthese twochromosomesoccur in CMLThe current5-yearoverallsurvival rateof CMLWhen togive H2RAswithdasatinibThe scoringsystem usedin chronicphaseI failed 3lines of TKIs,I can try thisagent nextI have theT315I mutationbut also haveelevated lipase60-70% ofpatients withCML presentwith thissymptomNumber ofblastspresent inacceleratedphaseThis TKI hasthe mostmetabolicsyndromeTherecommendedcriteria usedfor acceleratedphaseAfter 3months, I have3% BCR-ABL,I have this TKIresponseModerateto highemetogenicrisk TKIsPercentageof blastspresent inthe blastphaseDrug classthatrevolutionizedCMLtreatmentI avoid thisdrug classwith bosutinib,nilotinib anddasatinibI want toavoid thisTKI if I donot wantdiarrheaThelandmarkfor thefirst TKINon-pharmacologicaltreatment forCMLToo many ofthese bloodcells areabnormal inCMLResponsewhen BCR-ABL1 (IS)is <0.01%Patients havepresence of thisBCR-ABLproteinindicative ofCML TKIs aremajorsubstratesfor this liverenzymeThe numberof distinctclinicalphases inCMLTreatmentfor blastphaseCMLTranslocationbetweenthese twochromosomesoccur in CMLThe current5-yearoverallsurvival rateof CMLWhen togive H2RAswithdasatinibThe scoringsystem usedin chronicphaseI failed 3lines of TKIs,I can try thisagent nextI have theT315I mutationbut also haveelevated lipase60-70% ofpatients withCML presentwith thissymptom

Chronic Myeloid Leukemia BINGO - Call List

(Print) Use this randomly generated list as your call list when playing the game. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
O
2
O
3
N
4
I
5
G
6
B
7
N
8
I
9
B
10
G
11
O
12
N
13
B
14
B
15
I
16
O
17
I
18
G
19
I
20
G
21
B
22
O
23
N
24
G
  1. O-Number of blasts present in accelerated phase
  2. O-This TKI has the most metabolic syndrome
  3. N-The recommended criteria used for accelerated phase
  4. I-After 3 months, I have 3% BCR-ABL, I have this TKI response
  5. G-Moderate to high emetogenic risk TKIs
  6. B-Percentage of blasts present in the blast phase
  7. N-Drug class that revolutionized CML treatment
  8. I-I avoid this drug class with bosutinib, nilotinib and dasatinib
  9. B-I want to avoid this TKI if I do not want diarrhea
  10. G-The landmark for the first TKI
  11. O-Non-pharmacological treatment for CML
  12. N-Too many of these blood cells are abnormal in CML
  13. B-Response when BCR-ABL1 (IS) is <0.01%
  14. B-Patients have presence of this BCR-ABL protein indicative of CML
  15. I-TKIs are major substrates for this liver enzyme
  16. O-The number of distinct clinical phases in CML
  17. I-Treatment for blast phase CML
  18. G-Translocation between these two chromosomes occur in CML
  19. I-The current 5-year overall survival rate of CML
  20. G-When to give H2RAs with dasatinib
  21. B-The scoring system used in chronic phase
  22. O-I failed 3 lines of TKIs, I can try this agent next
  23. N-I have the T315I mutation but also have elevated lipase
  24. G-60-70% of patients with CML present with this symptom